News Image

Analyzing NYSE:PFE's Dividend Potential.

By Mill Chart

Last update: Oct 10, 2023

PFIZER INC (NYSE:PFE) is a hidden gem unveiled by our stock screening tool, featuring a promising dividend outlook alongside solid fundamentals. NYSE:PFE demonstrates decent financial health and profitability while ensuring a sustainable dividend. Let's break it down further.

Dividend Assessment of NYSE:PFE

ChartMill assigns a proprietary Dividend Rating to each stock. The score is computed by evaluating various valuation aspects, like the yield, the history, the dividend growth and sustainability. NYSE:PFE was assigned a score of 8 for dividend:

  • With a Yearly Dividend Yield of 4.90%, PFE is a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 3.93, PFE pays a better dividend. On top of this PFE pays more dividend than 97.14% of the companies listed in the same industry.
  • PFE's Dividend Yield is rather good when compared to the S&P500 average which is at 2.76.
  • PFE has paid a dividend for at least 10 years, which is a reliable track record.
  • PFE has not decreased their dividend for at least 10 years, which is a reliable track record.

Health Assessment of NYSE:PFE

Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NYSE:PFE has achieved a 5 out of 10:

  • With a decent Altman-Z score value of 2.68, PFE is doing good in the industry, outperforming 72.86% of the companies in the same industry.
  • With an excellent Debt to FCF ratio value of 6.13, PFE belongs to the best of the industry, outperforming 84.76% of the companies in the same industry.
  • A Current Ratio of 2.12 indicates that PFE has no problem at all paying its short term obligations.

Profitability Analysis for NYSE:PFE

ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NYSE:PFE, the assigned 8 is a significant indicator of profitability:

  • Looking at the Return On Assets, with a value of 9.75%, PFE belongs to the top of the industry, outperforming 90.95% of the companies in the same industry.
  • PFE's Return On Equity of 21.68% is amongst the best of the industry. PFE outperforms 91.90% of its industry peers.
  • The Return On Invested Capital of PFE (11.96%) is better than 90.00% of its industry peers.
  • The last Return On Invested Capital (11.96%) for PFE is well below the 3 year average (16.16%), which needs to be investigated, but indicates that PFE had better years and this may not be a problem.
  • Looking at the Profit Margin, with a value of 27.55%, PFE belongs to the top of the industry, outperforming 94.76% of the companies in the same industry.
  • PFE has a better Operating Margin (31.21%) than 95.71% of its industry peers.
  • PFE's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 68.78%, PFE is in the better half of the industry, outperforming 74.29% of the companies in the same industry.

Every day, new Best Dividend stocks can be found on ChartMill in our Best Dividend screener.

For an up to date full fundamental analysis you can check the fundamental report of PFE

Keep in mind

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

PFIZER INC

NYSE:PFE (4/29/2024, 10:29:08 AM)

25.745

+0.35 (+1.36%)

PFE News

News Image2 hours ago - Zacks Investment ResearchWhy Pfizer (PFE) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

News Image3 hours ago - The Business JournalsPfizer gene therapy made in NC gets FDA approval. It costs $3.5M per dose
News Image4 hours ago - The Motley Fool3 Beaten-Down Stocks I Wouldn't Touch With a 10-Foot Pole

These stocks aren't bargains.

News Image5 hours ago - Pfizer Inc.Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting
News Image6 hours ago - InvestorPlace3 Dividend Stocks to Buy on the Dip: April 2024

With the market presenting many vagaries, investors may take some solace in these dividend stocks to buy on the dip.

News Image17 hours ago - The Business JournalsPfizer gene therapy made in NC gets FDA approval. It costs $3.5M per dose

Pfizer's huge facility in Sanford produces its first FDA-approved gene therapy, which runs $3.5 million a dose.

News Imagea day ago - The Motley FoolIs Viking Therapeutics Incredibly Undervalued?

The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.

News Imagea day ago - The Motley Fool3 High-Yield Dividend Stocks That Could Soar 22% to 49%, According to Wall Street

Whether or not these stocks hit analysts' price targets, they all should be attractive to investors seeking great income and solid growth.

News Image2 days ago - The Motley Fool3 Dividend Stocks to Buy and Hold for the Next Decade

You'll get dividends and more with these great stocks.

News Image2 days ago - InvestorPlace7 Dividend Stocks to Buy Now for Steady Returns in Any Market

Passive investors pay attention! Invest in the best of the best with these seven dividend stocks for steady returns.

News Image3 days ago - CNBCCramer's week ahead: Fed meeting and earnings from Apple, Amazon, Eli Lilly

CNBC's Jim Cramer on Friday walked investors through next week on Wall Street.

News Image3 days ago - Market News VideoJune 7th Options Now Available For Pfizer (PFE)
PFE Links
Follow us for more